ERBB2 and breast cancer: ADI significantly attenuated the relationship between race and hormone receptor positive, HER2‐negative breast cancer (proportion attenuated = 8.5%, 95% CI 4.1–16.6%) and CRC cancer (proportion attenuated = 7.3%, 95% CI 3.7 to 12.8%), and there was a significant interaction between race and ADI for lung (interaction RR = 1.22, p < 0.0001) and prostate cancer (interaction RR = 1.09, p = 0.00092).